ENDSULIN, Inc. is a pre-clinical stage gene therapy company focused on advancing its lead clinical candidate to treat Diabetes Mellitus. ENDSULIN’s novel technology aims to give millions greater euglycemic control by combining the extensively tested AAV8 platform with a patented liver-directed gene construct. The construct contains a regulatory element to precisely regulate insulin expression in response to fluctuating glucose levels in the blood.
NEWS
PROGRESS
This video shows two treated rats, an experimental control and an untreated rat (the smallest animal).
INCREDIBLE IMPACT
Not only could this treatment realistically reach millions of patients with Type 1 diabetes — early signs show it could potentially treat Type 2 diabetes, too.
2-4 insulin injections
every day, on average, to manage the disease. ►Fewer than 2k patients
receive pancreas transplants each year, worldwide. ►Leading cause
of kidney failure, blindness, and vascular disease. ►Even with diligent daily management, many patients still experience severe complications.